Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Protective effects of dexmedetomidine in diabetic myocardial ischemia-reperfusion injury
ChiCTR-IPR-16008341Phase 4Not yet recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dexmedetomidine in type 2 diabetes mellitus (T2DM) and myocardial ischemia-reperfusion injury (5 arms), sponsored by The First Hospital of Jilin University. Primary endpoints: Cardiac troponin I (cTnI), Lactate dehydrogenase (LDH) and 2 more. Planned start May 2016; status: not yet recruiting.
02
Drugs
dexmedetomidine
03
Conditions
type 2 diabetes mellitus (T2DM)myocardial ischemia-reperfusion injury
Beyond the preview
Go deeper on ChiCTR-IPR-16008341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16008341.